Clearmind Medicine

Join us in supporting a meaningful cause this February with ! 🚫🍷 Just a few days left!

This month, we're proud to support the Dry February initiative by the Canadian Cancer Society, encouraging everyone to go alcohol-free to raise funds for cancer research and support. Every dollar raised makes a difference! At Clearmind Medicine, we're committed to health and wellness, working on innovative solutions to reduce alcoholism and its impact. Let's stand together to make a positive change! Learn more and donate today: https://cancer.ca/en/ways-to-give/dry-feb

If you missed it... a few items to catch up on:

1) Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
www.clearmindmedicine.com/news-release/clearmind-medicine-receives-approval-from-the-israeli-ministry-of-health-to-commence-its-phase-i-iia-clinical-trial-of-cmnd-100-for-alcohol-use-disorder

2) Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
https://www.clearmindmedicine.com/news-release/clearmind-medicine-receives-patent-approval-for-its-psychedelic-based-treatment-of-binge-behaviors-in-china

3) ICPR 2024: OPEN has given us a special €100 discount code for our community! Use the code CLEARMIND100 when checking out your tickets here: https://icpr-conference.com/tickets

4) Replay: Traditional vs. Novel Psychedelics Webinar
https://www.clearmindmedicine.com/past-events/traditional-vs-novel-psychedelics

5) Subscribe to Clearmind Medicine's newsletter for the latest news and developments: https://bit.ly/CMNDNews

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

www.clearmindmedicine.com/news-release/clearmind-medicine-receives-approval-from-the-israeli-ministry-of-health-to-commence-its-phase-i-iia-clinical-trial-of-cmnd-100-for-alcohol-use-disorder

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

https://finance.yahoo.com/news/clearmind-medicine-receives-approval-commence-120600584.html

Curious about MEAI?

Watch this --> https://youtu.be/-RQikn6O3qw?si=FrV1893YfFlUxIKG&t=34

They Call it The Miracle: What if a novel psychedelic could be the solution to alcoholism? What if a novel psychedelic could be the solution to one of society's most complicated and expensive mental health issues: Alcohol Use Disorder?Web: https://...

Learn more: https://bit.ly/cmnd-patents

The latest patent applications build upon Clearmind’s broad IP protection in the psychedelic space, which now includes 27 granted patents and 24 pending patent applications across 15 patent families.

https://bit.ly/cmnd-patents

"Clearmind continues to be at the forefront of the psychedelic market with one of the largest IP portfolios in the industry."

https://finance.yahoo.com/news/clearmind-medicine-submits-three-international-121400567.html

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

https://finance.yahoo.com/news/scisparc-clearmind-continue-strengthen-international-121400800.html

SciSparc

"We are pleased to continue our ongoing collaboration with Clearmind by expanding the intellectual property portfolio, which is an important asset," said SciSparc’s Chief Executive Officer, Oz Adler. "We believe in the added value that CannAmide™ can offer when combined with various psychedelic compounds that are known for their therapeutics advantages."

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds TEL AVIV, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of i...

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classical Psychedelic-Based Compounds

The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (L*D), psilocybin, N,N-dimethyltryptamine (DMT) and SciSparc's Palmitoylethanolamide(PEA), the active ingredient of SciSparc's proprietary CannAmide™.

https://www.clearmindmedicine.com/news-release/clearmind-medicine-submits-three-international-patent-applications-for-next-generation-of-innovative-psychedelic-based-compounds

Learn more about Clearmind Medicine: https://www.clearmindmedicine.com/

If you haven't had a chance to watch it yet, here is the replay of Rick Doblin's conversation with Clearmind Medicine CEO Dr. Adi Zuloff-Shani and VP of Business Development Mark Haden.

Traditional vs. Novel Psychedelics Webinar Replay:
https://www.clearmindmedicine.com/past-events/traditional-vs-novel-psychedelics

Clearmind Medicine Rick Doblin, Ph.D., is the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS). His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and ma*****na, primarily as prescription medicines but also for personal growth for ot...

Join our Newsletter 📰

Sign up now at https://bit.ly/CMNDNews and be the first to receive the latest news and developments straight to your inbox.

Clearmind Medicine Inc (CSE:CMND, NASDAQ:CMND) CEO Dr. Adi Zuloff-Shani joined Steve Darling from Proactive to announce a significant milestone for the company: the granting of divisional patent approval by the China National Intellectual Property Administration (CNIPA).

https://www.proactiveinvestors.com/companies/news/1040966/clearmind-medicine-receives-patent-approval-in-china-for-treatment-of-binge-behaviours-1040966.html

Clearmind Medicine receives Patent Approval in China for treatment of binge behaviours Clearmind Medicine Inc (CSE:CMND, NASDAQ:CMND) CEO Dr. Adi Zuloff-Shani joined Steve Darling from Proactive to announce a significant milestone for the...

Clearmind Medicine: exploring a pathway out of alcohol abuse

https://crystalequityresearch.blogspot.com/2024/02/clearmind-medicine-exploring-pathway.html

Clearmind Medicine: exploring a pathway out of alcohol abuse PRIME SERIES Clearmind Medicine (CMND) is a clinical stage pharmaceutical company with the promising CMND-100 candidate at the front en...

Missed our Virtual Investor Conference: Psychedelics for Obesity?

Professor Tam discusses the challenges of obesity, and the promising pre-clinical results with MEAI

Watch replay: https://www.clearmindmedicine.com/past-events/psychedelics-for-obesity

Read more: https://www.clearmindmedicine.com/news-release/clearmind-medicine-receives-patent-approval-for-its-psychedelic-based-treatment-of-binge-behaviors-in-china

If you missed it... a few items to catch up on:

1) Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
https://www.clearmindmedicine.com/news-release/clearmind-medicine-receives-patent-approval-for-its-psychedelic-based-treatment-of-binge-behaviors-in-china

2) ICPR 2024: OPEN has given us a special €100 discount code for our community! Use the code CLEARMIND100 when checking out your tickets here: https://icpr-conference.com/tickets

3) Replay: Traditional vs. Novel Psychedelics Webinar
https://www.clearmindmedicine.com/past-events/traditional-vs-novel-psychedelics

4) Subscribe to Clearmind Medicine's newsletter for the latest news and developments: https://bit.ly/CMNDNews

Join us in supporting a meaningful cause this February with ! 🚫🍷

This month, we're proud to support the Dry February initiative by the Canadian Cancer Society, encouraging everyone to go alcohol-free to raise funds for cancer research and support. Every dollar raised makes a difference! At Clearmind Medicine, we're committed to health and wellness, working on innovative solutions to reduce alcoholism and its impact. Let's stand together to make a positive change! Learn more and donate today: https://cancer.ca/en/ways-to-give/dry-feb

Read more about the latest with Clearmind: https://bit.ly/cmnd-china

Read more about the latest with MEAI: https://bit.ly/cmnd-china

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China

Clearmind’s IP portfolio consists of fifteen utility patent families, including patents and applications having method of use and composition of matter claims which includes 24 pending patent applications and 27 granted patents in major jurisdictions such as the US, Europe, China, and India.

https://www.clearmindmedicine.com/news-release/clearmind-medicine-receives-patent-approval-for-its-psychedelic-based-treatment-of-binge-behaviors-in-china

If you missed it... a few items to catch up on:

1) Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
https://www.clearmindmedicine.com/news-release/clearmind-medicine-announces-exclusive-long-term-licensing-agreement-with-leading-israeli-research-center

2) ICPR 2024: OPEN has given us a special €100 discount code for our community! Use the code CLEARMIND100 when checking out your tickets here: https://icpr-conference.com/tickets

3) Replay: Traditional vs. Novel Psychedelics Webinar
https://www.clearmindmedicine.com/past-events/traditional-vs-novel-psychedelics

4) Subscribe to Clearmind Medicine's newsletter for the latest news and developments: https://bit.ly/CMNDNews

"This research also demonstrated MEAI’s unique ability to treat co***ne addiction and its potential to become, if approved by regulatory agencies, the first dedicated co***ne addiction treatment."

https://www.clearmindmedicine.com/news-release/clearmind-medicine-announces-exclusive-long-term-licensing-agreement-with-leading-israeli-research-center

***ne

Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center

The licensing agreement refers to the company's dedicated treatment for co***ne addiction which previously indicated a significant decrease in co***ne craving

Dr. Adi Zuloff-Shani, CEO of Clearmind, commented, “As a result of our successful pre-clinical trials that demonstrated MEAI’s effectiveness in reducing co***ne craving and addiction, we made the strategic decision to secure the long-term, exclusive rights to the technology, in order to lock-up the technology and ensure maximum returns for our shareholders. Millions are affected by co***ne addiction worldwide, and the successful application of MEAI [5-Methoxy-2-aminoindane] could revolutionize treatment protocols and offer new hope to those trapped in the cycle of addiction. This agreement is a further testament to our goal of providing innovative treatments for addiction using psychedelic compounds.”

https://www.clearmindmedicine.com/news-release/clearmind-medicine-announces-exclusive-long-term-licensing-agreement-with-leading-israeli-research-center

***ne

Read more: https://bit.ly/cmnd-obesity

Clearmind Medicine develops breakthrough treatments for binge behaviour and mental health, including alcohol use disorder, binge eating, depression and PTSD.

Learn more: https://www.clearmindmedicine.com/

If you missed it... a few items to catch up on:

1) Clearmind Medicine Completed Type A Meeting with the FDA https://www.clearmindmedicine.com/news-release/clearmind-medicine-completed-type-a-meeting-with-the-fda

2) From War Zones to Healing Minds (Psychology Today): https://bit.ly/war-zones-ptsd

3) Replay: Traditional vs. Novel Psychedelics Webinar
https://www.clearmindmedicine.com/past-events/traditional-vs-novel-psychedelics

4) Subscribe to Clearmind Medicine's newsletter for the latest news and developments: https://bit.ly/CMNDNews

Looking for the latest news and developments at Clearmind?

Subscribe to our newsletter: https://bit.ly/CMNDNews

ICPR 2024 is the sixth edition of Europe’s leading conference on psychedelic science andtherapy. Join the world’s top experts discussing rigorous science, critical perspectives, andpsychedelic therapies on June 6-8, 2024, in Haarlem, the Netherlands. ICPR has beenorganized by the since 2007.OPEN has given us a special €100 discount code for our community! Use the code CLEARMIND100 when checking out your tickets here:

ICPR 2024 - Europe's Conference on Psychedelic Research & Therapy Interdisciplinary Conference on Psychedelic Research 6 - 8 June, 2024 | Philharmonie, Haarlem | The Netherlands